Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated for reasons of either safety or efficacy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Piedmont Healthcare System | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the impact of painPRIMER in a prospective six-month clinical investigation looking at clinical outcomes, health care professional and patient satisfaction, healthcare resource use, productivity and direct and indirect costs. The hypothesis is that early identification of the presence of neuropathic pain and back pain related comorbidities, to direct appropriate pharmacologic and non-pharmacologic treatment, painPRIMER would improve patient outcomes and reduce patient cycling, inappropriate use of imaging and surgery, thereby reducing costs and productivity loss associated with these inefficiencies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| painPREMIER cohort |
| ||
| Control cohort |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| painPREMIER cohort | Device | Low back pain patients prospectively recruited during the study period and managed with painPREMIER. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Roland Morris Disability Questionnaire: Change from baseline to month 3 in the Roland Morris Disability Questionnaire (RMDQ) total score in the painPRIMER cohort vs control cohort | 3 month | |
| Low back pain (LBP) Cost: LBP (specific and related) direct medical costs associated with utilization of healthcare incurred by each study patient from baseline to month 6 | 6 month |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline to month 6 in RMDQ total score | 3 and 6 months | |
| Change from baseline to month 3 and 6 in low back pain intensity (LBPI) | 3 and 6 months | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Conditions that may impede the patient's ability to participate in painPRIMER and complete the questionnaires, as per the HCP's discretion
Patients presenting who have undergone surgery for back pain in the previous 12 months
Not provided
Not provided
Not provided
Patients with low back pain
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Fayetteville | Georgia | 30214 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D017116 | Low Back Pain |
| ID | Term |
|---|---|
| D001416 | Back Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Control cohort | Other | A matched group of low back pain patients not managed with painPREMIER. |
|
| Change from baseline to month 3 and 6 daily sleep interference rating scale (DSIRS) |
| 3 and 6 months |
| Response as defined as a the proportion of patients with at least 30% and 50% improvement in LBPI at 3 and 6 months | 3 and 6 months |
| Response as defined as a the proportion of patients with at least 30% and 50% improvement in RMDQ at 3 and 6 months | 3 and 6 months |
| Quality of Life in the painPRIMER cohort vs control cohort: Change from baseline to month 3 and 6 in the Short- Form. | 3 and 6 months |
| psychosocial outcomes in the painPRIMER cohort and control cohort: Proportion of patients at risk for depression and/or anxiety (via Patient Health Questionnaire-4 [PHQ-4]) at baseline, 3 and 6 months | 3 and 6 months |
| psychosocial outcomes in the painPRIMER cohort and control cohort: Changes from baseline to month 3 and 6 in patients at risk for depression (PHQ-8) and anxiety (GAD-7), among those receiving the instrument (NOTE: only given to those scoring >/= | 3 and 6 months |
| 3 on PHQ-4) | 3 and 6 months |
| psychosocial outcomes in the painPRIMER cohort and control cohort: Change from baseline to month 3 and 6 in catastrophizing (Coping Strategies Questionnaire -Catastrophizing [CSQ-CAT]) | 3 and 6 months |
| productivity/indirect costs: Changes from baseline to month 3 and 6 in Work Productivity and Activity Impairment (WPAI): Specific Health Problem, LBP | 3 and 6 months |
| Direct cost: Comparison of resource use/direct medical costs, in 6 months pre-enrollment/index date and 6 months post-enrollment/index date via insurance claims data for painPRIMER and control cohorts | 3 and 6 months |
| Patient satisfaction with painPRIMER | 3 and 6 months |
| Healthcare professional satisfaction with painPRIMER | 6 months |
| D013568 |
| Pathological Conditions, Signs and Symptoms |